CA2190598A1 - Pharmaceutical composition - Google Patents

Pharmaceutical composition

Info

Publication number
CA2190598A1
CA2190598A1 CA002190598A CA2190598A CA2190598A1 CA 2190598 A1 CA2190598 A1 CA 2190598A1 CA 002190598 A CA002190598 A CA 002190598A CA 2190598 A CA2190598 A CA 2190598A CA 2190598 A1 CA2190598 A1 CA 2190598A1
Authority
CA
Canada
Prior art keywords
cyclodextrin
beta
water
derivative
steroidal anti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002190598A
Other languages
English (en)
French (fr)
Inventor
Lawrence John Penkler
Lueta-Ann Glintenkamp
Mark David Bodley
Michiel Coenraad Bosch Van Oudtshoorn
Christopher Stubbs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Farmarc Nederland BV
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2190598A1 publication Critical patent/CA2190598A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
CA002190598A 1994-05-27 1995-05-22 Pharmaceutical composition Abandoned CA2190598A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA94/3740 1994-05-27
ZA943740 1994-05-27

Publications (1)

Publication Number Publication Date
CA2190598A1 true CA2190598A1 (en) 1995-12-07

Family

ID=25583939

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002190598A Abandoned CA2190598A1 (en) 1994-05-27 1995-05-22 Pharmaceutical composition

Country Status (6)

Country Link
EP (1) EP0760680A1 (pt)
JP (1) JPH10500982A (pt)
AU (1) AU2531295A (pt)
BR (1) BR9507768A (pt)
CA (1) CA2190598A1 (pt)
WO (1) WO1995032737A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA959469B (en) * 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
IT1283029B1 (it) * 1996-05-17 1998-04-03 Resa Farma Composizioni farmaceutiche a base di diclofenac
WO1996040077A2 (en) * 1995-06-07 1996-12-19 Quadrant Holdings Cambridge Limited Methods for stably incorporating substances within dry, foamed glass matrices and compositions obtained thereby
WO1996041646A2 (en) * 1995-06-13 1996-12-27 Dyer, Alison, Margaret Pharmaceutical compositions containing lornoxicam and cyclodextrin
IT1294205B1 (it) * 1997-07-23 1999-03-24 Farmigea Spa Procedimento per la solubilizzazione in acqua e in veicoli acquosi di sostanze farmacologicamente attive
US8231899B2 (en) * 1998-09-10 2012-07-31 Nycomed Danmark Aps Quick release pharmaceutical compositions of drug substances
CA2343148C (en) 1998-09-10 2005-11-15 Nycomed Danmark A/S Quick release pharmaceutical compositions of drug substances
ITMI20012749A1 (it) * 2001-12-21 2003-06-21 Chiesi Farma Spa Procedimento per la preparazione mediante trattamento con microonde di composti di inclusione tra farmaco e ciclodestrine e prodotti ottenut
AU2003257791A1 (en) * 2002-08-15 2004-03-29 Tong Liu Soild nano pharmaceutical formulation and preparation method thereof
JO3352B1 (ar) 2005-06-17 2019-03-13 Apr Applied Pharma Res Sa صيغ دايكلوفيناك وطرق استخدامه
KR20140038575A (ko) 2006-03-28 2014-03-28 자블린 파머슈티칼스 인코포레이티드 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
EP2394641A1 (en) 2010-05-30 2011-12-14 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Pharmaceutical formulations of lornoxicam

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT52263B (de) * 1911-04-22 1912-02-26 Jean Baptiste Feilner Verfahren zur Herstellung von photographischen Kombinationsnegativen.
HU176215B (en) * 1978-01-27 1981-01-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing a cyclodextrin-indomethacin inclusion complex with a ratio of at about 2:1
JPS5920230A (ja) * 1982-07-19 1984-02-01 チバ−ガイギ−・アクチエンゲゼルシヤフト ピルプロフエン含有薬剤
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
YU43290B (en) * 1986-11-13 1989-06-30 Lek Tovarna Farmacevtskih Process for preparing inclusioned complex of ibuproxane with beta-cyclodextrine
GB8813682D0 (en) * 1988-06-09 1988-07-13 Reckitt & Colmann Prod Ltd Pharmaceutical compositions
FR2647343B1 (fr) * 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
EP0491812A4 (en) * 1989-09-14 1992-11-04 Australian Commercial Research & Development Limited Drug delivery compositions
FR2660195B1 (fr) * 1990-03-28 1994-10-07 Crinex Sa Laboratoires Composition pharmaceutique a macher, antiinflammatoire et/ou analgesique.
EP0519428B1 (en) * 1991-06-21 2000-09-20 Takeda Chemical Industries, Ltd. Cyclodextrin compositions with fumagillol derivates
GB9207990D0 (en) * 1992-04-10 1992-05-27 Smithkline Beecham Plc Pharmaceutical composition

Also Published As

Publication number Publication date
EP0760680A1 (en) 1997-03-12
JPH10500982A (ja) 1998-01-27
WO1995032737A1 (en) 1995-12-07
AU2531295A (en) 1995-12-21
BR9507768A (pt) 1997-09-02

Similar Documents

Publication Publication Date Title
KR100349754B1 (ko) 제약조성물
US5646131A (en) Method for solubilizing drugs using cyclodextrins and carboxylic acids
SK35696A3 (en) Water-soluble nimesulide salt, preparation method thereof, its water solution, nimesulide based combinations and their use
JP2001513563A (ja) 溶解性および生物学的利用能の改良されたメロキシカムの医薬組成物
CA2190598A1 (en) Pharmaceutical composition
HUT64961A (en) Inclusion complexes of clavulanic acid with hydrophylic and hydrophobic beta-cyclodextrin derivatives and method for producint them
US5164380A (en) Process for preparing piroxicam/cyclodextrin complexes, the products obtained and their pharmaceutical compositions
CA2494157C (en) Inclusion complexes of butylphthalide with cyclodextrin or its derivatives, a process for their preparation and the use thereof
WO2001041757A1 (fr) Composition pharmaceutique contenant de la cyclodextrine
EP1374906B1 (en) A process for the preparation of piroxicam: beta-cyclodextrin inclusion compounds
US5597583A (en) Pharmaceutical composition
JP3417942B2 (ja) ニメスリドとシクロデキストリンの包接化合物
JPH07509498A (ja) 新規なニメスライド塩／シクロデキストリン包接錯体
EP1347780B1 (en) Compositions of n-(methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides
WO1996041646A2 (en) Pharmaceutical compositions containing lornoxicam and cyclodextrin
WO1995007104A1 (en) Inclusion complexes of beta-cyclodextrin with flurbiprofen, ketoprofen and naproxen
AU3075395A (en) Inclusion complexes of ranitidine
NZ292895A (en) Compositions comprising a estramustine (estradiol 3-bis(2-chloroethyl)carbamate) derivative and cyclodextrin
JPS58116423A (ja) メタノプロスタサイクリン製剤組成物

Legal Events

Date Code Title Description
FZDE Dead